[CAS NO. 943609-66-3] Vedolizumab

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-P9911
Brand:	MCE
CAS:	943609-66-3

Overview

MDL	-
Molecular Weight	146814.90
Molecular Formula	-
SMILES	[Vedolizumab]

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Anal Chim Acta. 2021, 338306.

Summary

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

IC50 & Target

Integrin ^[1]

In Vitro

Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC ₅₀ =0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC ₅₀ =0.02-0.06 μg/mL) and fibronectin (IC ₅₀ =0.02 μg/mL), but not vascular cell adhesion molecule 1 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02674308	Takeda	Ulcerative Colitis and Crohn´s Disease	March 24, 2015
NCT00783718	Millennium Pharmaceuticals, Inc.	Ulcerative Colitis	January 2009	Phase 3
NCT03961308	Takeda	Healthy Volunteers	March 12, 2018	Phase 1
NCT04779307	Takeda	Colitis, Ulcerative	October 19, 2021	Phase 3
NCT05442567	Takeda	Ulcerative Colitis\|Crohn´s Disease	February 28, 2023	Phase 3
NCT03029143	Takeda	Colitis, Ulcerative	March 29, 2017	Phase 4
NCT02723006	Millennium Pharmaceuticals, Inc.\|Takeda	Melanoma	June 22, 2016	Phase 1
NCT04919252	Yonsei University	Crohn´s Disease and Ulcerative Colitis	June 1, 2021	Phase 3
NCT04362735	Pontifícia Universidade Católica do Paraná\|Takeda	Crohn Disease	August 1, 2020
NCT02497469	Takeda	Colitis, Ulcerative	June 29, 2015	Phase 3
NCT03329209	Takeda	Colitis, Ulcerative\|Crohn Disease	March 5, 2018	Phase 1
NCT03802214	Stanford University\|Takeda\|University of Western Ontario, Canada\|University of California, San Diego	Ulcerative Colitis	October 29, 2020
NCT03375424	Ced Service GmbH	Inflammatory Bowel Diseases\|Treatment	October 2, 2017
NCT04006080	Guy´s and St Thomas´ NHS Foundation Trust\|Takeda	Ulcerative Colitis	July 1, 2019	Phase 4
NCT03196427	Takeda\|Takeda Development Center Americas, Inc.	Ulcerative Colitis\|Crohn´s Disease	July 30, 2018	Phase 2
NCT03558152	Genentech, Inc.	Ulcerative Colitis	October 26, 2018	Phase 2
NCT03949621	Takeda	Healthy Volunteers	February 6, 2018	Phase 1
NCT01981616	Millennium Pharmaceuticals, Inc.	Inflammatory Bowel Disease	September 2011	Phase 1
NCT01177228	Millennium Pharmaceuticals, Inc.	Ulcerative Colitis	May 2007	Phase 2
NCT03657160	Millennium Pharmaceuticals, Inc.\|Takeda	Hematopoietic Stem Cells	February 6, 2019	Phase 3
NCT05386290	Peking Union Medical College Hospital	Ulcerative Colitis\|Crohn Disease	July 9, 2020
NCT01224171	Millennium Pharmaceuticals, Inc.	Crohn´s Disease	November 2010	Phase 3
NCT02993783	Millennium Pharmaceuticals, Inc.\|Takeda	Allogeneic Hematopoietic Stem Cell Transplantation	April 28, 2017	Phase 2
NCT05481619	Second Affiliated Hospital, School of Medicine, Zhejiang University	Ulcerative Colitis	January 1, 2021	Phase 4
NCT05158517	Groupe d´Etude Therapeutique des Affections Inflammatoires Digestives\|Takeda	Inflammatory Bowel Diseases	March 20, 2022
NCT02760615	Takeda	Colitis, Ulcerative\|Crohn Disease	November 1, 2016	Phase 4
NCT02630966	Takeda	Crohn´s Disease	August 10, 2016	Phase 4
NCT02712866	Parc de Salut Mar	Inflammatory Bowel Disease	January 2017
NCT03035058	Takeda	Primary Sclerosing Cholangitis\|Inflammatory Bowel Disease	February 2017	Phase 3
NCT02611830	Takeda	Colitis, Ulcerative	December 18, 2015	Phase 3
NCT03885713	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Inflammatory Bowel Diseases\|Crohn Disease\|Ulcerative Colitis	September 10, 2019	Phase 4
NCT03824561	Takeda	Ulcerative Colitis	February 1, 2019
NCT02039505	Takeda	Ulcerative Colitis	February 4, 2014	Phase 3
NCT02820493	Universita degli Studi di Genova	Crohn Disease	September 2016	Phase 4
NCT02611817	Takeda	Crohn´s Disease	January 4, 2016	Phase 3
NCT02646683	Geert D´Haens\|Takeda\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Crohn Disease	July 2015	Phase 4
NCT02790138	Takeda	Pouchitis	October 12, 2016	Phase 4
NCT02878083	Nantes University Hospital\|Takeda\|Mauna Kea Technologies\|Institut National de la Santé Et de la Recherche Médicale, France	ULCERATIVE COLITIS	January 11, 2017	Not Applicable
NCT03221036	Takeda	Moderately to Severely Active Ulcerative Colitis	August 3, 2017	Phase 3
NCT02620046	Takeda	Colitis, Ulcerative\|Crohn´s Disease	April 15, 2016	Phase 3
NCT02972450	ANRS, Emerging Infectious Diseases\|European Commission\|Swiss Government\|Medical Research Council\|FIT Biotech Ltd.\|Fred Hutchinson Cancer Center\|University College, London\|Centre Hospitalier Universitaire Vaudois\|Imperial College London\|Istituto Nazionale Malattie Infettive Lazaro Spallanzani\|Universitätsklinikum Hamburg-Eppendorf\|Institut d´Investigacions Biomèdiques August Pi i Sunyer\|Henri Mondor University Hospital\|European Georges Pompidou Hospital\|Saint-Louis Hospital, Paris, France	HIV-1-infection	February 20, 2019	Phase 1\|Phase 2
NCT02834754	Marc Schwartz\|Takeda\|University of Pittsburgh	Crohn´s Disease	December 1, 2018	Phase 2
NCT02163421	Takeda	Healthy	June 2014	Phase 1
NCT03819296	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Clinical Stage 0 Cutaneous Melanoma AJCC v8\|Clinical Stage I Cutaneous Melanoma AJCC v8\|Clinical Stage IA Cutaneous Melanoma AJCC v8\|Clinical Stage IB Cutaneous Melanoma AJCC v8\|Clinical Stage II Cutaneous Melanoma AJCC v8\|Clinical Stage IIA Cutaneous Melanoma AJCC v8\|Clinical Stage IIB Cutaneous Melanoma AJCC v8\|Clinical Stage IIC Cutaneous Melanoma AJCC v8\|Clinical Stage III Cutaneous Melanoma AJCC v8\|Clinical Stage IV Cutaneous Melanoma AJCC v8\|Colitis\|Lung Non-Small Cell Carcinoma\|Malignant Genitourinary System Neoplasm\|Malignant Solid Neoplasm\|Pathologic Stage 0 Cutaneous Melanoma AJCC v8\|Pathologic Stage I Cutaneous Melanoma AJCC v8\|Pathologic Stage IA Cutaneous Melanoma AJCC v8\|Pathologic Stage IB Cutaneous Melanoma AJCC v8\|Pathologic Stage II Cutaneous Melanoma AJCC v8\|Pathologic Stage IIA Cutaneous Melanoma AJCC v8\|Pathologic Stage IIB Cutaneous Melanoma AJCC v8\|Pathologic Stage IIC Cutaneous Melanoma AJCC v8\|Pathologic Stage III Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8\|Pathologic Stage IIID Cutaneous Melanoma AJCC v8\|Pathologic Stage IV Cutaneous Melanoma AJCC v8\|Stage 0 Lung Cancer AJCC v8\|Stage I Lung Cancer AJCC v8\|Stage IA1 Lung Cancer AJCC v8\|Stage IA2 Lung Cancer AJCC v8\|Stage IA3 Lung Cancer AJCC v8\|Stage IB Lung Cancer AJCC v8\|Stage II Lung Cancer AJCC v8\|Stage IIA Lung Cancer AJCC v8\|Stage IIB Lung Cancer AJCC v8\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	February 21, 2021	Phase 1\|Phase 2
NCT02862132	Shaare Zedek Medical Center	Crohn´s Disease\|Ulcerative Colitis\|Inflammatory Bowel Disease	January 2017	Not Applicable
NCT03629379	Universitaire Ziekenhuizen KU Leuven	Inflammatory Bowel Diseases\|Psoriasis	September 1, 2018	Phase 4
NCT04797325	University of Copenhagen	Immune-Mediated Colitis	August 30, 2021	Phase 2
NCT03219359	Aaron Etra\|Icahn School of Medicine at Mount Sinai	Crohn Disease	July 12, 2017	Phase 2
NCT02788175	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	HIV	May 28, 2016	Phase 1
NCT03309865	Mayo Clinic	Ulcerative Colitis\|Dietary Modification	December 25, 2017	Early Phase 1
NCT02953275	University of Miami\|Takeda	Crohn Disease	April 13, 2017	Early Phase 1
NCT03948581	Takeda	Healthy Volunteers	February 21, 2018	Phase 1
NCT02929316	AGA Clinical Research Associates, LLC\|Takeda	Celiac Disease	June 25, 2018	Phase 2
NCT02694588	University Hospital Schleswig-Holstein	IBD	June 2014	Not Applicable
NCT02324699	Icahn School of Medicine at Mount Sinai\|Takeda	Crohn´s Disease	April 2016	Phase 4
NCT03138655	Takeda\|Takeda Development Center Americas, Inc.	Ulcerative Colitis\|Crohn´s Disease	November 8, 2017	Phase 2
NCT02743806	Takeda	Colitis, Ulcerative\|Crohn Disease	August 1, 2016	Phase 4
NCT02646657	Geert D´Haens\|Takeda\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Colitis, Ulcerative	July 2015	Phase 4
NCT04738942	Takeda	Ulcerative Colitis\|Crohn´s Disease	June 4, 2021	Phase 3
NCT02768532	Centre Hospitalier Universitaire de Saint Etienne\|Theradiag\|Takeda	Crohn Disease	July 1, 2016	Phase 4
NCT03234907	Takeda	Crohn´s Disease	August 3, 2017	Phase 3
NCT04002180	Takeda	Crohn´s Disease	July 1, 2019
NCT03237260	University of Pennsylvania\|Takeda\|Corporal Michael J. Crescenz VA Medical Center	Ulcerative Colitis	July 1, 2017	Phase 4
NCT02038920	Takeda	Crohn´s Disease	January 28, 2014	Phase 3
NCT00790933	Takeda	Ulcerative Colitis\|Crohn´s Disease	May 22, 2009	Phase 3
NCT04120415	ANRS, Emerging Infectious Diseases\|EuroVacc Foundation\|European AIDS Treatment Group (EATG)\|Medical Research Council\|University College London Hospitals\|University of Liverpool\|Erasmus Medical Center\|Henri Mondor University Hospital\|European Georges Pompidou Hospital\|Saint-Louis Hospital, Paris, France\|Centre Hospitalier Universitaire Vaudois\|Chelsea and Westminster Hospital, UK\|Universitätsklinikum Hamburg-Eppendorf\|Hospital Clinic of Barcelona\|Istituto Nazionale Malattie Infettive Lazaro Spallanzani\|Imperial College London\|Institut d´Investigacions Biomèdiques August Pi i Sunyer\|European Commission\|Swiss Government	HIV-1-infection	June 21, 2022	Phase 2
NCT02913508	Takeda	Ulcerative Colitis\|Crohn´s Disease	April 2014	Phase 2
NCT02954159	Medical College of Wisconsin\|Takeda	Ulcerative Colitis	May 18, 2017	Phase 3
NCT03961295	Takeda	Healthy Volunteers	February 22, 2018	Phase 1
NCT04804540	Takeda	Ulcerative Colitis\|Crohn Disease	December 29, 2021	Phase 4
NCT03147859	Ottawa Hospital Research Institute\|CHEO Research Institute\|Nebraska Centre for Substance Abuse Research	HIV-infection+AIDS	November 1, 2017	Phase 2
NCT02559713	Takeda	Colitis, Ulcerative\|Crohn´s Disease	November 29, 2017	Phase 4
NCT00783692	Millennium Pharmaceuticals, Inc.	Crohn´s Disease	December 2008	Phase 3
NCT04407247	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Colitis\|Lung Non-Small Cell Carcinoma\|Malignant Genitourinary System Neoplasm\|Malignant Solid Neoplasm\|Melanoma	July 9, 2020	Phase 1\|Phase 2
NCT03142321	Washington University School of Medicine	Crohn Disease of Small Intestine	June 8, 2018	Phase 4
NCT02678052	Takeda\|The Organization of Teratology Information Specialists	Colitis, Ulcerative\|Crohn´s Disease	December 1, 2015
NCT03679546	Rennes University Hospital	Ulcerative Colitis	January 4, 2019	Phase 4
NCT03043677	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Inflammatory Bowel Disease	April 1, 2016
NCT00619489	Millennium Pharmaceuticals, Inc.	Ulcerative Colitis\|Crohn´s Disease	December 2007	Phase 2
NCT04779320	Takeda	Crohn´s Disease (CD)	April 30, 2022	Phase 3
NCT02764762	Takeda	Crohn Disease	June 12, 2017	Phase 4
NCT03577782	Hospitales Universitarios Virgen del Rocío\|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	HIV Infections	September 2018	Phase 1\|Phase 2
NCT05281614	Benaroya Research Institute\|University of California, San Diego	Type 1 Diabetes	August 1, 2022	Early Phase 1
NCT02425111	Takeda	Crohn´s Disease	March 30, 2015	Phase 3
NCT02728895	Takeda	Allogeneic Hematopoietic Stem Cell Transplantation	June 15, 2016	Phase 1
NCT05205603	Sixth Affiliated Hospital, Sun Yat-sen University	Ulcerative Colitis\|Efficacy, Self\|Biologics\|Mesalazine	January 15, 2022	Phase 4
NCT04469062	Eli Lilly and Company	Ulcerative Colitis	April 20, 2021	Phase 3

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.
[2] Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart